Ken Griffin Protara Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,400 shares of TARA stock, worth $21,756. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,400
Previous 3,800
121.05%
Holding current value
$21,756
Previous $15,000
13.33%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding TARA
# of Institutions
43Shares Held
10.4MCall Options Held
25KPut Options Held
12.7K-
Opaleye Management Inc. Boston, MA2.3MShares$5.97 Million1.23% of portfolio
-
Ra Capital Management, L.P. Boston, MA1.9MShares$4.92 Million0.06% of portfolio
-
Stem Point Capital LP New York, NY984KShares$2.55 Million0.6% of portfolio
-
Boxer Capital, LLC San Diego, CA812KShares$2.1 Million0.09% of portfolio
-
Baker Bros. Advisors LP New York, NY537KShares$1.39 Million0.01% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $29.2M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...